These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin]. Matsuoka H, Yano K, Baba H, Kounoe S, Seo Y, Saito T, Tomoda H, Wakasugi H. Gan To Kagaku Ryoho; 1995 Sep; 22(11):1644-6. PubMed ID: 7574783 [Abstract] [Full Text] [Related]
3. Experimental study concerning safety dosage of OK-432 for intrauterine treatment. Ogita K, Taguchi T, Suita S. Asian J Surg; 2006 Jul; 29(3):202-6. PubMed ID: 16877226 [Abstract] [Full Text] [Related]
4. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Kirkwood JM, Wilson J, Whiteside TL, Donnelly S, Herberman RB. Cancer Immunol Immunother; 1997 May; 44(3):137-49. PubMed ID: 9191873 [Abstract] [Full Text] [Related]
5. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation. Homma S, Sagawa Y, Komita H, Koido S, Nagasaki E, Ryoma Y, Okamoto M. Cancer Immunol Immunother; 2007 Aug; 56(8):1265-74. PubMed ID: 17219148 [Abstract] [Full Text] [Related]
7. [Local immunotherapy for cancer]. Hattori T, Niimoto M, Toge T, Hamamoto S, Seto Y, Kameda A, Tomoda S. Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1157-61. PubMed ID: 6503978 [Abstract] [Full Text] [Related]
8. Augmentation of interleukin 1 and interleukin 2 production by OK-432. Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N. Int J Immunopharmacol; 1985 Sep; 7(2):263-70. PubMed ID: 3874175 [Abstract] [Full Text] [Related]
9. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Yamaguchi Y, Satoh Y, Miyahara E, Noma K, Funakoshi M, Takashima I, Sawamura A, Toge T. Anticancer Res; 1995 Sep; 15(5B):2201-6. PubMed ID: 8572625 [Abstract] [Full Text] [Related]
12. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Tanaka N, Gouchi A, Ohara T, Mannami T, Konaga E, Fuchimoto S, Okamura S, Sato K, Orita K. Cancer; 1994 Dec 15; 74(12):3097-103. PubMed ID: 7982173 [Abstract] [Full Text] [Related]
15. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment. Yamaguchi Y, Ohshita A, Kawabuchi Y, Hihara J, Miyahara E, Noma K, Toge T. Int J Oncol; 2004 Apr 15; 24(4):959-66. PubMed ID: 15010836 [Abstract] [Full Text] [Related]
16. Intratumoral injection of OK-432 suppresses metastatic squamous cell carcinoma lesion inducing interferon-γ and tumour necrosis factor-α. Akeda T, Yamanaka K, Kitagawa H, Kawabata E, Tsuda K, Kakeda M, Omoto Y, Habe K, Isoda K, Kurokawa I, Mizutani H. Clin Exp Dermatol; 2012 Mar 15; 37(2):193-4. PubMed ID: 21883396 [No Abstract] [Full Text] [Related]
19. [Combined effects of cis-DDP and OK-432 on ascitic mastocytoma in mice: optimal period for the administration of OK-432]. Komatsu K, Nakamura W. C R Seances Soc Biol Fil; 1986 Mar 15; 180(1):117-20. PubMed ID: 2943364 [Abstract] [Full Text] [Related]